Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms

References

• Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann NY Acad Sci 1999;878:159–78
   PubMed Web of Science ®Google Scholar
• Grange JJ, Davis V, Baxter BT. Pathogenesis of abdominal aortic aneurysm: update and look toward the future. Cardiovasc Surg 1997;5:256–65
   Google Scholar
• Ailawadi G, Eliason JL, Upchurch Jr GR. Current concepts in the pathogenesis of abdominal aortic aneurysms. J Vasc Surg 2003;38:584–8
   Google Scholar
• Hollier LH, Taylor LM, Ochsner J. Recommended indications for operative treatment of abdominal aortic aneurysms. J Vasc Surg 1992;15:1046–56
   Google Scholar
• MacSweeney STR, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg 1994, 81:935–41
   Google Scholar
• Shah PK. Inflammation, metalloproteinases and increased proteolysis. An emerging pathophysiological paradigm in aortic aneurysm. Circulation 1997;96:2115–7
   Google Scholar
• Wills A, Thompson MM, Crowther M, Sayers RD, Bell RF. Pathogenesis of abdominal aortic aneurysms – cellular and biochemical mechanisms. Eur J Vasc Endovasc Surg 1996;12:391–400
   Google Scholar
• He CM, Roach MR. The composition and mechanical properties of abdominal aortic aneurysms. J Vasc Surg 1994;20:6–13
   PubMed Web of Science ®Google Scholar
• Baxter BT, Davis VA, Minion DJ, Wang Y, Lynch TG, McManus BC. Abdominal aortic aneurysms are associated with altered matrix proteins of the nonaneurysmal aortic segments. J Vasc Surg 1994;19:797–803
   PubMed Web of Science ®Google Scholar
• Huffman MD, Curci JA, Moore G, Kerns BD, Starcher BC, Thompson RW. Functional importance of connective tissue repair during the development of experimental abdominal aortic aneurysms. Surgery 2000;128:429–38
   PubMed Web of Science ®Google Scholar
• Holmes DR, Liao S, Parks WC, Thompson RW. Medial neovascularization in abdominal aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J Vasc Surg 1995;21:761–72
   PubMed Web of Science ®Google Scholar
• Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad and the ugly. 2002;90:251–62
   Google Scholar
• Minion DJ, Davis VA, Nejezchleb PA, Wang Y, Lynch TG, McManus BM. Elastin is increased in abdominal aortic aneurysms. J Surg Res 1994;57:443–6
   PubMed Web of Science ®Google Scholar
• MacSweeney STR, Young G, Greenhalg RM, Powell JT. Mechanical properties of the aneurysmal aorta. Br J Surg 1992;79:1281–4
   PubMed Web of Science ®Google Scholar
• Rao SK, Mathrubutham M, Sherman D, Cerveira J, Cohen JR. Reduced capacity to inhibit elastase in abdominal aortic aneurysm. J Surg Res 1999;82:24–7
   Google Scholar
• Fillinger MF, Marra SP, Raghavan ML, Kennedy FE. Prediction of rupture risk in abdominal aortic aneurysm during observation: wall stress versus diameter. J Vasc Surg 2003;37:724–32
   PubMed Web of Science ®Google Scholar
• Newman KM, Ogata Y, Malon AM, et al. Identification of matrix metalloproteinase 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 1994;14:1315–20
   PubMed Web of Science ®Google Scholar
• Thompson RW, Holmes DR, Mertens RA, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. J Clin Invest 1995;96:318–26
   PubMed Web of Science ®Google Scholar
• Reilly JM, Sicard GA, Lucore CL. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vasc Surg 1994;19:865–72
   Google Scholar
• Allaire E, Hasenstab D, Richard D, et al. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor – 1. Circulation 1998;98:249–55
   PubMed Web of Science ®Google Scholar
• Louwerns HD, Kwaan HC, Rearce WH, Yao JST, Verrusio E. Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture. Eur J Vasc Endovasc Surg 1995;10:289–93
   Google Scholar
• Wassef M, Baxter BT, Chisholm RL, et al. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung and Blood Institute. J Vasc Surg 2001;34:730–8
   PubMed Web of Science ®Google Scholar
• Yamashita A, Noma T, Nakazawa A, et al. Enhanced expression of matrix metalloproteinases-9 in abdominal aortic aneurysms. World J Surg 2001;25:259–65
   PubMed Web of Science ®Google Scholar
• Tamarina NA, McMillan WD, Shively VP, Pearce WH. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997;122:264–72
   PubMed Web of Science ®Google Scholar
• Palombo D, Maione M, Cifiello BI, Udini M, Maggio D, Lupo M. Matrix metalloproteinases. Their role in degenerative chronic diseases of abdominal aorta. J Cardiovasc Surg. 1999;40:257–60
   Google Scholar
• Knox JB, Sukhova GK, Whittermore AD, Libby P. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997;95:205–12
   PubMed Web of Science ®Google Scholar
• Deng GG, Martin-McNulty B, Sukovich DA, et al. Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res 2003;92:510–7
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Proteinases in cardiovascular aneurysms and rupture: targets for therapy? J Clin Invest 2000;105:1519–20
   PubMed Web of Science ®Google Scholar
• Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625–32
   PubMed Web of Science ®Google Scholar
• Boyle JR, McDermott E, Crowther M, Wills AD, Bell PRF, Thompson MM. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg 1998;27:354–61
   PubMed Web of Science ®Google Scholar
• Verloes A, Sakalihasan N, Limet R, Koulitcher R. Genetic aspects of abdominal aortic aneurysms. Ann NY Acad Sci 1996;800:44–55
   PubMed Web of Science ®Google Scholar
• Viijmen-van Keulen CJ, Pals G, Rauwerda JA. Familial abdominal aortic aneurysm: a systemic review of genetic background. Eur J Vasc Surg 2002;24:105–16
   Google Scholar
• Kuivaniemi H, Shibamura H, Arthur C, et al. Familial abdominal aortic aneurysms: collections of 233 multiplex families. J Vasc Surg 2003;37:340–5
   PubMed Web of Science ®Google Scholar
• Turley EA. Extracellular matrix remodeling. Multiple paradigms in vascular disease. Circ Res 2001;88:2–4
   Google Scholar
• Davies MJ. Aortic aneurysm formation. Lessons from human studies and experimental models. Circulation 1998;98:193–95
   Web of Science ®Google Scholar
• Freestone T, Turner R, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995;15:1145–51
   PubMed Web of Science ®Google Scholar
• Yajima N, Masuda M, Miyazaki M, Nakajima N, Chien S, Shyy JYJ. Oxidative stress is involved in the development of experimental abdominal aortic aneurysm: a study of the transcription profile with complementary DNA microarray. J Vasc Surg 2002;36:379–85
   PubMed Web of Science ®Google Scholar
• Reed D, Reed C, Stemmermann G, Hayashi T. Are aortic aneurysms caused by atherosclerosis? Circulation 1992;85:205–11
   PubMed Web of Science ®Google Scholar
• Chang JB, Stein TA, Liu JP, Dunn ME. Risk factors associated with rapid growth of small abdominal aortic aneurysms. Surgery 1997;121:117–22
   PubMed Web of Science ®Google Scholar
• Visse R, Negase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 2003;92:827–39
   PubMed Web of Science ®Google Scholar
• Lesauskaite V, Tanganelli P, Sassi C, et al. Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases and their inhibitors. Hum Pathol 2001;32:1003–11
   PubMed Web of Science ®Google Scholar
• Negase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491–4
   PubMed Web of Science ®Google Scholar
• Wang Y, Johnson AR, Ye QZ, Dyer RD. Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain. J Biol Chem 1999;274:33043–49
   PubMed Web of Science ®Google Scholar
• Wang X, Yi J, Lei J, Pei D. Expression, purification and characterization of recombinant mouse MT5MMP protein products. FEBS Letters 1999;462:261–6
   PubMed Web of Science ®Google Scholar
• English WR, Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25). FEBS Letters 2001;491:137–4
   PubMed Web of Science ®Google Scholar
• Lijen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001;86:324–33
   PubMed Web of Science ®Google Scholar
• Yang M, Kurkinnen M. Cloning and characterization of a novel matrix metalloproteinases, CMMP, from chicken embryo fibroblasts. J Biol Chem 1998;273:17893–900
   PubMed Web of Science ®Google Scholar
• Strackle JO, Fosang AJ, Last K, et al. Matrix metalloproteinase 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein. FEBS Letters 2000;478:52–6
   PubMed Web of Science ®Google Scholar
• Loftus IM, Naylor AR, Bell PRF, Thompson MM. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002;89:680–4
   PubMed Web of Science ®Google Scholar
• Ferrans VJ. New insights into the world of matrix metalloproteinases. Circulation 2002;105:405–7
   PubMed Web of Science ®Google Scholar
• Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann NY Acad Sci 1996;800:157–74
   PubMed Web of Science ®Google Scholar
• Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863–8
   Google Scholar
• Nollendorfs A, Greiner TC, Nagase H, Baxter T. The expression and localization of membrane type-1 matrix metalloproteinase in human abdominal aortic aneurysms. J Vasc Surg 2001;34:316–22
   PubMed Web of Science ®Google Scholar
• Annabi B, Shedid D, Ghosn P, et al. Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms. J Vasc Surg. 2002;35:539–46
   PubMed Web of Science ®Google Scholar
• Nakahashi TK, Hoshina K, Tsao PS, et al. Flow loading induces macrophage antioxidative gene expression in experimental aneurysms. Arterioscler Thromb Vasc Biol 2002;22:2017–22
   PubMed Web of Science ®Google Scholar
• Schneiderman J, Bordin GM, Adar R, et al. Patterns of expression of fibrinolytic genes and matrix metalloproteinase-9 in dissecting aortic aneurysm. Am J Pathol 1998;152:703–10
   PubMed Web of Science ®Google Scholar
• Jones JT, Phillips VL, Harris EL, Rossaak JI, van Rij AM. Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm. J Vasc Surg 2003;38:1363–7
   Google Scholar
• McMillan WD, Patterson BK, Keen RR, Shively VP, Cipollone M, Pearce W. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive and normal aorta. Arterioscler Thromb Vasc Biol 1995;15:1139–44
   PubMed Web of Science ®Google Scholar
• Saito S, Zempo N, Yamashita A, Takenaka H, Fujoka K, Esato K. Matrix metalloproteinase expressions in arteriosclerotic aneurysmal disease. Vasc Endovasc Surg 2002;36:1–7
   PubMedGoogle Scholar
• Davis V, Persidskaia R, Baca-Regen L, et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 1998;18: 1625–33
   Google Scholar
• Ailawadi G, Knipp BS, Lu G, et al. A nonintrisic regional basis for increased infrarenal aortic MMP-9 expression and activity. J Vasc Surg 2003;37:1059–66
   PubMed Web of Science ®Google Scholar
• Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatine B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000;105:1641–49
   PubMed Web of Science ®Google Scholar
• Carell TWG, Burnand KG, Wells GMA, Clements JM, Smith A. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2002;105: 477–82
   Google Scholar
• Tung WS, Lee JK, Thompson RW. Simultaneous analysis of 1176 gene products in normal human aorta and abdominal aortic aneurysms using a membrane-based complementary DNA expression array. J Vasc Surg 2001;34: 143–50
   Google Scholar
• McMillan WD, Tamarina NA, Cipollone M, Jonshon DA, Parker MA, Pearce WH. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 1997;96:2228–32
   PubMed Web of Science ®Google Scholar
• McMillan WD, Pearce WH. Increased plasma levels of matalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999;29:122–29
   PubMed Web of Science ®Google Scholar
• Petersen E, Gineitis A, Wagberg F, Angquist KA. Activity of matrix metalloproteinases-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg 2000;20:457–61
   PubMed Web of Science ®Google Scholar
• Petersen E, Wagberg F, Angquist KA. Proteolysis of the abdominal aortic aneurysm wall and the association with rupture. Eur J Vasc Endovasc Surg 2002;23:153–57
   Google Scholar
• Crowther M, Goodball S, Jones JL, Bell PR, Thompson MM. Increased matrix metalloproteinases 2 expression in vascular smooth muscle cells cultured from abdominal aortic aneurysms. J Vasc Surg 2000;32: 575–83
   Google Scholar
• McMillan WD, Patterson BK, Keen RR, Pearce WH. In situ localization and quantification of seventy-two-kilodalton type IV collagenase in aneurismal, occlusive and normal aorta. J Vasc Surg 1995;22:295–305
   PubMed Web of Science ®Google Scholar
• Allaire E, Muscatelli-Groux B, Mandet C, et al. Paracrine effect of vascular smooth muscle cells in the prevention of aortic aneurysm formation. J Vasc Surg 2002;36:1018–26
   PubMed Web of Science ®Google Scholar
• Goodball S, Porter KE, Bell PR, Thompson MM. Enhanced invasive properties exhibited by smooth muscle cells are associated with elevated production of MMP-2 in patients with aortic aneurysms. Eur J Vasc Endovasc Surg 2002;24:72–80
   PubMed Web of Science ®Google Scholar
• Crowther M, Goodall S, Jones JL, Bell PR, Thompson. Localization of matrix metalloproteinase 2 within the aneurysmal and normal aortic wall. Br J Surg 2000;87: 1391–400
   Google Scholar
• Goodball S, Crowther M, Hemingway DM, Bell PR, Thompson MM. Ubiquitous elevation of matrix metalloproteinases-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 2001;104: 304–9
   Google Scholar
• Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW. Expression and localization of macrophage elastase (matrix metalloproteinae-12) in abdominal aortic aneurysm. J. Clin Invest 1998;102: 1900–10
   Google Scholar
• Carmeliet P, Moons L, Lijen R, et al. Urokinase-generated plasminactivates matrix metalloproteinases during aneurysm formation. Nat Genet 1997;17:439–44
   PubMed Web of Science ®Google Scholar
• Irazarry E, Newman KM, Gandhi RH, et al. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res 1993;54:571–74
   PubMed Web of Science ®Google Scholar
• Newman KM, Jean-Claude J, Li H, Scholes JV, Ogata Y, Negase H, Tilson MD. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg 1994;20:814–20
   PubMed Web of Science ®Google Scholar
• Mao D, Lee JK, VanVickle SJ, Thompson RW. Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem Biophys Res Commun 1999;261:904–10
   PubMed Web of Science ®Google Scholar
• Nakamura M, Tachieda R, Niinuma H, et al. Circulating biochemical marker levels of collagen metabolism are abnormal in patients with abdominal aortic aneurysm. Angiology 2000;51:385–91
   PubMed Web of Science ®Google Scholar
• Allaire E, Forough R, Clowes M, Starcher B, Clowes AW. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 1998;102: 1413–20
   Google Scholar
• Kaito K, Urayama H, Watanabe G. Doxycycline treatment in a model of early abdominal aortic aneurysm. Surg Today 2003;33:426–33
   Google Scholar
• Lemaitre V, Soloway PD, D’Armiento J. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation 2003;107: 333–38
   Google Scholar
• Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res 2002;90: 897–903
   Google Scholar
• Yoon S, Tromp G, Vongpunsawad S, Ronkainen A, Yuvonen T, Kuivaniemi H. Genetic analysis of MMP3, MMP9 and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun 1999;265:563–68
   PubMed Web of Science ®Google Scholar
• Peters DJ, Kassam A, Jean PLS, Yonas H, Ferell RE. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999;30: 2612–16
   Google Scholar
• Armstrong PJ, Johanning JM, Calton Jr WC, et al. Differential gene expression in human abdominal aorta: aneurysmal versus occlusive disease. J Vasc Surg 2002;35:346–55
   PubMed Web of Science ®Google Scholar
• Wang X, Tromp G, Cole CW, et al. Analysis of coding sequences for tissue inhibitor of metalloproteinases 1 (TIMP1) and 2 (TIMP2) in patients with aneurysms. Matrix Biol 1999;18:121–24
   PubMed Web of Science ®Google Scholar
• Bown MJ, Burton PR, Horsburgh T, Nicholson ML, Bell PR, Sayers RD. The role of cytokine gene polymorphisms in the pathogenesis of abdominal aortic aneurysms: a case-control study. J Vasc Surg 2003;37:999–1005
   PubMed Web of Science ®Google Scholar
• Prall AK, Longo GM, Mayhan WG, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 2002;35:923–9
   PubMed Web of Science ®Google Scholar
• Lindholt JS, Vammen S, Fasting H, Henneberg EW, Heickendorff L. The plasma level of matrix metalloproteinases 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur J Vasc Endovasc Surg 2000;20: 281–85
   Google Scholar
• Cypers P, Buth J, Harris PL, Gevers E, Lahey PR. Realistic expectations for patients with stent-graft treatment of abdominal aortic aneurysms: results of a European multicentre registry. Eur J Vasc Endovasc Surg 1999;17:507–16
   Google Scholar
• Karch LA, Hernetta JP, Hodgson K, et al. Algorithm for the diagnosis and treatment of endoleaks. Am J Surg 1999;178:234–41
   Google Scholar
• Lorelli DR, Jean-Claude JM, Fox CJ, et al. Response of plasma matrix metalloproteinase-9 to conventional abdominal aortic aneurysm repair or endovascular exclusion: implications for endoleak. J Vasc Surg 2002;35:916–22
   PubMed Web of Science ®Google Scholar
• Sangiorgi G, D’Averio R, Mauriello A, et al. Plasma levels of metalloproteinase-3 and 9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation 2001;104(Suppl):I288–95
   Google Scholar
• Limet R, Sakalihassan N, Albert A. Determination of the expansion rate and incidence of rupture of abdominal aortic aneurysms. J Vasc Surg 1991;14:540–8
   Google Scholar
• Wolf YG, Thomas WS, Brennan FJ, Goff WG, Sise MJ, Bernstein EF. Computed tomography scanning associated with rapid expansion abdominal aortic aneurysms. J Vasc Surg 1994;20:529–38
   PubMed Web of Science ®Google Scholar
• Katz DA, Littenberg B, Cronewett JL. Management of small abdominal aortic aneurysms: early surgery vs watchful waiting. JAMA 1992;268:2678–86
   Google Scholar
• UK Small Aneurysm Trial Participants. Mortality results for randomized controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998;352:1649–55
   Google Scholar
• Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92-kD gelatinase. J Vasc Surg 1996;23:336–46
   PubMed Web of Science ®Google Scholar
• Curci JA, Mao D, Bohner DG, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000;31:325–42
   PubMed Web of Science ®Google Scholar
• Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998;28:1082–93
   Google Scholar
• Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A. role of matrix metalloproteinases in blood flow-induced arterial enlargement. Arterioscler Thromb Vasc Biol 2000;20:120–6
   PubMed Web of Science ®Google Scholar
• Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483–8
   Google Scholar
• Prall AK, Longo GM, Mayhan WG, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: Comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 2002;35:923–9
   PubMed Web of Science ®Google Scholar
• Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg 2002; 36:1–12
   PubMed Web of Science ®Google Scholar
• Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind placebo-controlled pilot study. J Vasc Surg 2001;34:606–10
   PubMed Web of Science ®Google Scholar
• Petersen E, Boman J, Wagberg F, Angquist KA. Presence of chlamydia pneumoniae in abdominal aortic aneurysms is not associated with increased activity of matrix metalloproteinases. Eur J Vasc Surg 2002;24:365–9
   Google Scholar
• Davis V, Persidskaia R, Baca-Regen LM, Fiotti N, Halloran BG, Baxter T. Cytokine pattern in aneurysmal and occlusive disease of the aorta. J Surg Res 2001;101:152–6
   Google Scholar
• Holmes DR, Petrinec D, Weste W, Thompson RW, Reilly JM. Indomethacin prevents elastase-induced abdominal aortic aneurysms. J Surg Res 1996;63:305–9
   Google Scholar
• Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms. Implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999;100:48–54
   Google Scholar
• Gadowski GR, Pilcher DB, Ricci MA. Abdominal aortic aneurysm expansion rate: effect of size and beta-adrenergic blockade. J Vasc Surg 1994;19:727–31
   Google Scholar
• Slaiby JM, Ricci MA, Gadowski GR, Hendley ED, Pilcher DB. Expansion of aortic aneurysms is reduced by propranolone in a hypertensive rat model. J Vasc Surg 1994;20:178–83
   Google Scholar
• Treharne GD, Boyle JR, Goodball S, Loftus IM, Bell PRF, Thompson MM. Marimastat inhibits elastin degradation and matrix metalloproteinases 2 activity in a model of aneurysm disease. Br J Surg 1999;86:1053–58
   PubMed Web of Science ®Google Scholar
• Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G, Franklin DP, Youkey JR. The matrix metalloproteinase BB-94 limits expansion of experimntal abdominal aortic aneurysms. J Vasc Surg 1999;29: 130–9
   Google Scholar
• Moore G, Liao S, Curci JA, et al. Suppression of experimental abdominal aortic aneurysms by systematic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). J Vasc Surg 1999;29:522–32
   PubMed Web of Science ®Google Scholar
• Abbruzzese TA, Guzman RJ, Martin RL, Yee C, Zarins CK, Dalman RL. Matrix metalloproteinase inhibition limits arterial enlargement in a rodent arteriovenous fistula model. Surgery 1998;124:328–35
   PubMed Web of Science ®Google Scholar
• Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671–8
   PubMed Web of Science ®Google Scholar
• Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003;19:540–56
   PubMed Web of Science ®Google Scholar
• Nagashima H, Aoka Y, Sakomura Y, et al. A 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002;36:158–63
   PubMed Web of Science ®Google Scholar